Welcome to our dedicated page for Invivyd news (Ticker: IVVD), a resource for investors and traders seeking the latest updates and insights on Invivyd stock.
Invivyd, Inc. develops monoclonal antibody therapies for serious viral infectious diseases, with an initial focus on SARS-CoV-2. Company news commonly covers PEMGARDA (pemivibart), which received U.S. FDA emergency use authorization for pre-exposure prevention of COVID-19 in certain immunocompromised individuals, and pipeline work involving VYD2311 for COVID-19, VBY329 for RSV, and VMS063 for measles.
Updates also address clinical-study design and tolerability research, antibody platform presentations, financial results and corporate updates, public education efforts around antibodies and immune health, and Nasdaq inducement equity grants under the company’s 2026 Inducement Plan.
Invivyd (Nasdaq: IVVD) launched a national education campaign, Antibodies for Any Body, in partnership with skier Lindsey Vonn on April 7, 2026. The campaign debut includes AntibodiesforAnyBody.com and an interactive Wellness Assessment to explain antibodies and lifestyle links to immune health.
The site offers accessible resources about antibody function and how sleep, nutrition, and activity may support immune protection; visitors are encouraged to consult their doctor about personalized habits.
Invivyd (Nasdaq: IVVD) announced inducement option grants made April 1, 2026, to 16 newly hired non-executive employees totaling 1,083,750 options under the Invivyd 2026 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The options carry a per-share exercise price of $1.33 (closing price on the grant date), vest over four years with 25% after one year and monthly vesting thereafter, and have a 10-year term, subject to plan terms and continuous service.
Invivyd (Nasdaq: IVVD) announced that Chief Scientific Officer Robert Allen, Ph.D. presented at the World Vaccine Congress Washington on March 30, 2026.
His talk, titled “Developing mAb Therapies that Keep Pace with Rapidly Evolving Viral Threats,” addressed monoclonal antibody scalability, access, economics, and strategies to manage virus variation, and highlighted Invivyd’s bespoke platform for vulnerable populations.
Invivyd (Nasdaq: IVVD) reported full-year 2025 net product revenue for PEMGARDA of $53.4M and Q4 2025 PEMGARDA revenue of $17.2M (Q4 YoY +25%). Cash and cash equivalents were $226.7M at year-end after >$200M raised in 2H 2025. DECLARATION Phase 3 enrollment is complete; top-line VYD2311 data expected mid-2026. FDA granted Fast Track for VYD2311 in Dec 2025. R&D expense fell to $38.3M and net loss narrowed to $52.5M for 2025.
Invivyd (Nasdaq: IVVD) appointed Michael Mina, M.D., Ph.D., as Chief Medical Officer effective March 5, 2026. Dr. Mina brings expertise in infectious disease epidemiology, immunology, and clinical strategy, with more than 100 scientific publications and 10,000 citations.
His background includes academic posts at Harvard and leadership roles in diagnostics and digital health, and he will support Invivyd’s monoclonal antibody prevention and treatment pipeline.
Invivyd (Nasdaq: IVVD) will host a conference call on March 5, 2026 at 8:30 a.m. ET to discuss fourth-quarter and full-year 2025 financial results and provide a corporate update.
Interested parties can access a live webcast and analysts can join the Q&A via designated links; a recording will be posted to the company investor relations website shortly after the event.
Invivyd (Nasdaq: IVVD) granted inducement stock options to four newly hired non-executive employees on March 1, 2026, totaling 192,000 shares under the 2026 Inducement Plan.
The options carry a $1.69 exercise price (closing price Feb 27, 2026), vest over four years (25% after one year, then monthly), have a 10-year term, and were granted under Nasdaq Listing Rule 5635(c)(4).
Invivyd (Nasdaq: IVVD) published a peer-reviewed correlate-of-protection model that links serum monoclonal antibody levels to clinical protection against symptomatic COVID-19 across multiple Omicron-era variants.
The model, using CANOPY Phase 3 data for pemivibart, aligns with observed outcomes and predicts meaningful protection even at low antibody concentrations, supporting variant-agnostic assessment of COVID mAbs.
Invivyd (Nasdaq: IVVD) said it is aligned with the U.S. FDA on LIBERTY, a Phase 3 trial to compare safety and immunology of its monoclonal antibody candidate VYD2311 versus mRNA COVID vaccines and to study co-administration.
The FDA requested specific monitoring of myocarditis/pericarditis adverse events of special interest for LIBERTY; DECLARATION Phase 3 topline data remain expected mid-2026 with ~1,770 total participants.
Invivyd (Nasdaq: IVVD) announced a national multimedia education partnership with champion skier Lindsey Vonn to raise public awareness about antibodies and infectious disease prevention. The campaign is planned to launch in early Spring 2026, with Vonn serving as the public spokesperson to connect antibody science to health and wellness. Vonn, a decorated Olympian and 84-time World Cup winner who returned to competition in 2024 and qualified in December for the Milan Cortina 2026 Olympic Winter Games, will help translate antibody concepts into accessible guidance for the American public.